# Lucid Diagnostics (LUCD) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LUCD
## Company Profile
- Ticker: LUCD
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics, Oncology
## Stock Data
- Close: 1 USD
- Market cap: 196479879.95000002 USD
- Last updated: 2026-08-05
## Business Overview
### Esophageal Cancer Prevention Company
Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.
### EsoGuard and EsoCheck
The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection device. Together, the products are designed to identify at-risk patients before esophageal cancer develops.
### Commercial and Reimbursement Model
Lucid generates revenue from processed EsoGuard tests while building adoption through gastroenterologists, health systems, commercial payers, Medicare, and the Veterans Health Administration.
## Why The Stock Is Moving

Following the latest company update, “Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test”, LUCD closed up 4.25% at $1.00 on Aug 5, 2026. The move occurred in the trading session associated with this commercial update.

## Future Catalysts

- The main thing to watch at Lucid Diagnostics is its latest development priorities. The update that sharpened the story was the next company-specific pipeline update. That is the part of the story investors will probably keep circling back to.

## Recent News
- 2026-08-05 12:46 EST — [Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-secures-commercial-coverage-policy-spanning-multiple-health-pl-9b974f96) — Source: Lucid Diagnostics
- 2026-08-04 12:30 EST — [Lucid Diagnostics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-9b811364) — Source: Lucid Diagnostics
- 2026-07-30 12:30 EST — [Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-second-quarter-2026-business-update-conference-call-an-fdcc99f1) — Source: Lucid Diagnostics
- 2026-05-14 12:00 EST — [Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Lucid Diagnostics
- 2026-04-30 12:31 EST — [Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026](https://biopharmsignal.com/news/LUCD/lucid-diagnostics-to-hold-first-quarter-2026-business-update-conference-call-and-ef5e4a87) — Source: Lucid Diagnostics